BSE filing, BSE: 544220. Summary written from the filing by ALFA Finder's alert engine.
Clinitech Laboratory Ltd: key numbers
- Share price
- ₹30.00
- Market cap
- ₹6.85 Cr
- Revenue (annual)
- ₹9.49 Cr
- Net profit (annual)
- ₹0.42 Cr
- P/E (TTM)
- 16.4×Sector 36.2×
- Promoter holding
- 64.62%
- FII holding
- 0.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Clinitech Laboratory Ltd
All →Clinitech Laboratory H1 FY27 Results: Net Profit ₹0.4 Cr, Up 33.3% YoY
Clinitech Laboratory Ltd reported revenue from operations of ₹9.4 Cr (+84.3% YoY) and net profit of ₹0.4 Cr (+33.3% YoY) for H1 FY27.
- Key figure
- Net profit ₹0.4 Cr · +33.3% YoY
Clinitech Laboratory Board Meeting Date
Clinitech Laboratory intimated BSE of a board meeting on 13 November 2026 to approve unaudited half-year results and note an internal audit report. The trading window stays closed until 48 hours after the results.
Clinitech Laboratory Other Announcement
Clinitech Laboratory submitted a certificate confirming the non-applicability of SEBI Regulation 23 regarding Related Party Transactions. This is for the half-year ended September 30, 2026.
Clinitech Laboratory Promoter Reclassification
Clinitech Laboratory Ltd reclassified 12,000 shares held by Mr. Siddhesh Nayak on behalf of Kamaxi Stock Trendz from 'Public' to 'Promoter Group' category.
Clinitech Laboratory Other Announcement
Clinitech Laboratory Limited filed a Regulation 74(5) compliance certificate for the quarter ended September 30, 2026, confirming no rematerialization requests were received.
Clinitech Laboratory Annual General Meeting
Clinitech Laboratory Limited held its 16th Annual General Meeting on September 24, 2026. Shareholders transacted items including financial statement adoption and director re-appointment.
Other other announcement announcements
All →Religare Enterprises Other Announcement
Religare Enterprises filed CARE Ratings' monitoring agency report for the quarter ended September 30, 2026, on its Rs 1,500 crore preferential warrant issue. The report states proceeds were used per the offer document with no deviation.
Optivalue Tek Consulting Other Announcement
Optivalue Tek filed Acuité's half-yearly monitoring report on IPO proceeds for H1 FY2026-27. No deviation from the offer objects was observed.
5Paisa Capital Other Announcement
5paisa Capital Ltd filed its quarterly shareholding pattern under Regulation 31(1)(c). It reports routine holding figures with no new transaction or corporate event.
Chennai Meenakshi Multispeciality Hospital Other Announcement
Chennai Meenakshi Multispeciality Hospital issued a duplicate share certificate for 100 shares to Inder Chand Kothari L under folio 00008717. The intimation is routine share-certificate paperwork with no transaction or money involved.
Axel Polymers Other Announcement
Axel Polymers reports no deviation in utilisation of its Rs 11.18 Crore preferential issue proceeds for the quarter ended 30 September 2026. This is a routine Regulation 32 statement of deviation with a clean auditor certificate.
360 One Wam Other Announcement
360 ONE WAM disclosed PIT sales by five insiders on 12 November 2026, totalling about Rs 3.55 Crore. The sellers are designated persons, KMP and an employee's relative, with no promoter involved.
- Value
- ₹3.55 Cr